Erratum: Department of Error (First-line treatment of advanced colorectal cancer (2011) 377(9783) (2060–2062), (S0140673611607885), (10.1016/S0140-6736(11)60788-5));First-line treatment of advanced colorectal cancer

The Lancet

Volumn 377, Issue 9783, 2011, Pages 2060-2062

  Hewish, Madeleine ^a   Cunningham, David ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; GENE MUTATION; HUMAN; METASTASIS; NOTE; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79959336704     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60920-3     Document Type: Erratum

References (15)

1. TS Maughan, RA Adams, CG Smith on behalf of the MRC COIN Trial Investigators Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 2011 10.1016/S0140-6736(11)60613-2 published online June 4.
2. D Cunningham, W Atkin, HJ Lenz et al. Colorectal cancer Lancet 375 2010 1030 1047
3. A Dewdney, D Cunningham, J Tabernero et al. EXPERT-C: a randomized phase II European multicenter trial of neoadjuvant chemotherapy (capecitabine/ oxaliplatin) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined high-risk rectal cancer J Clin Oncol 29 suppl 4 2011 360 (abstr).
4. L Dahan, A Sadok, JL Formento, JF Seitz, H Kovacic Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines Br J Pharmacol 158 2009 610 620
5. E Van Cutsem, CH Kohne, I Lang et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 2011 2011 2019
6. TA176 Cetuximab for the first-line treatment of metastatic colorectal cancer 2009 National Institute for Health and Clinical Excellence London
7. De Roock W B Claes, D Bernasconi et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
8. W De Roock, DJ Jonker, F Di Nicolantonio et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 2010 1812 1820
9. E Hawkes, D Cunningham Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies J Clin Oncol 28 2010 e529 e531
10. A Oden-Gangloff, F Di Fiore, F Bibeau et al. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy Br J Cancer 100 2009 1330 1335
11. M Scartozzi, I Bearzi, A Mandolesi et al. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients Br J Cancer 104 2011 1786 1790
12. Mekenkamp L, Tol J, Dijkstra J, et al. Beyond KRAS mutation status: influence of KRAS copy number alteration and microRNAs in response to cetuximab in metastatic colorectal cancer patients. AACR Annual Meeting, Orlando, Florida; April 2-6, 2011; 235 (abstr).
13. J Pander, H Gelderblom, NF Antonini et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer Eur J Cancer 46 2010 1829 1834
14. RA Adams, AM Meade, MT Seymour on behalf of the MRC COIN Trial Investigators Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet Oncol 2011 10.1016/S1470-2045(11)70102-4 published online June 4.
15. B Chibaudel, F Maindrault-Goebel, G Lledo et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study J Clin Oncol 27 2009 5727 5733